Protagonist Therapeutics (PTGX) Accumulated Depreciation (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Accumulated Depreciation of $8.7 million for Q1 2026, up 4.89% sequentially from $8.3 million in Q4 2025, and up 19.91% YoY from $7.3 million in Q1 2025.
Protagonist Therapeutics (PTGX) Accumulated Depreciation (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Accumulated Depreciation for 12 years, with the latest figure at $8.7 million in Q1 2026.
- Quarterly Accumulated Depreciation rose 19.91% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 19.91% YoY) and the FY2025 annual result came in at $8.3 million, up 18.19% from the prior year.
- Accumulated Depreciation climbed to $8.7 million in Q1 2026 per PTGX's latest filing, from $8.3 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $8.7 million in Q1 2026 and troughed at $4.5 million in Q1 2022.
- A 5-year average of $6.5 million and a median of $6.5 million in 2024 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation advanced 23.39% in 2022, then rose 12.43% in 2025.
- Over 5 years, Accumulated Depreciation stood at $5.3 million in 2022, then grew by 18.65% to $6.2 million in 2023, then increased by 12.85% to $7.0 million in 2024, then gained by 18.19% to $8.3 million in 2025, then rose by 4.89% to $8.7 million in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $8.7 million, $8.3 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.12 Mn |
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | 8.32 Mn |
| Sep 30, 2025 | 7.94 Mn |
| Jun 30, 2025 | 7.58 Mn |
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Sep 30, 2024 | 6.93 Mn |
| Jun 30, 2024 | 6.70 Mn |
| Mar 31, 2024 | 6.47 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Sep 30, 2023 | 5.95 Mn |
| Jun 30, 2023 | 5.72 Mn |
| Mar 31, 2023 | 5.49 Mn |
| Dec 31, 2022 | 5.25 Mn |
| Sep 30, 2022 | 4.97 Mn |
| Jun 30, 2022 | 4.74 Mn |
| Mar 31, 2022 | 4.53 Mn |
| Dec 31, 2021 | 4.26 Mn |
| Dec 31, 2020 | 3.47 Mn |